Study on the efficacy of Qi Shi Shen Shu Capsule combined with dapagliflozin in the treatment of type 2 diabetic nephropathy
10.3969/j.issn.1671-8348.2025.04.011
- VernacularTitle:芪石肾舒胶囊联合达格列净治疗2型糖尿病肾病的疗效研究
- Author:
Yueli PU
1
;
Changying ZHAO
;
Chunmei ZHENG
;
Lijuan WU
;
Yonglin LI
;
Yao MING
;
Hongwei LI
Author Information
1. 西南医科大学附属中医医院内分泌代谢科,四川泸州 646000
- Keywords:
diabetic nephropathy;
diabetes mellitus,type 2;
sodium-glucose cotransporter 2 inhibitor;
Qi Shi Shen Shu Capsule;
Dapagliflozin
- From:
Chongqing Medicine
2025;54(4):858-862
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of Qi Shi Shen Shu Capsule combined with dapagliflozin in treating type 2 diabetic nephropathy.Methods 120 patients with type 2 diabetic nephropathy(qi-yin liangxu syndrome)admitted to the endocrinology department in the inpatient and outpatient depart-ments of endocrinology from May 2022 to December 2023 were randomly divided into control and observation groups(60 cases each).The control group received dapagliflozin plus placebo capsules,while the observation group received dapagliflozin plus Qi Shi Shen Shu Capsule for 6 months.The therapeutic effects were observed between the two groups.Parameters including serum creatinine(Scr),urinary albumin-to-creatinine ratio(uACR),24-hour urinary protein quantification(24hUP),glycated hemoglobin(HbA1c),and tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and high sensitivity-C reactive protein(hs-CRP)were measured be-fore and after treatment.Results The total effective rate was higher(P＜0.05)in the observation group(93.33％)than in the control group(78.33％).After treatment,both groups showed decreased levels of uACR,Scr,24hUP,HbA1c,TNF-α,IL-6,and hs-CRP compared with baseline,with lower levels in the obser-vation group(P＜0.05).Conclusion Qi Shi Shen Shu Capsule combined with dapagliflozin can effectively re-duce uACR,Scr levels and serum inflammatory cytokines levels in patients with type 2 diabetic nephropathy.
